Glasdegib Disease Interactions

Patients treated with glasdegib can develop QTc prolongation and ventricular arrhythmias, including ventricular fibrillation and ventricular tachycardia. The clinical trial excluded patients with baseline QTc of greater than 470 ms or with a history of long QT syndrome or uncontrolled cardiovascular disease. Monitor electrocardiograms (ECGs) and electrolytes closely in patients under treatment. In patients with congenital long QT syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring is recommended. Interrupt glasdegib if QTc increases to greater than 500 ms, and discontinue permanently for patients who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia

Glasdegib has not been studied in patients with severe renal impairment or moderate-to-severe hepatic impairment. Caution is advised.